For tumor cases described so far, prognosis of children with infant-type hemispheric glioma seems to be better compared with the other pediatric-type high-grade gliomas with significant differences between the molecular alterations: For a group of 27 patients in total, 5‐year overall survival was 53.8%, 25.0% and 42.9% for patients with ALK, ROS1, and NTRK fusions of the tumors, respectively [93]. The gene discussed is ROS1; the disease is glioma.